Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$59.04 -1.4%	$61.69	$43.70 ▼ $86.53	$1.88B	-1.44	45,122 shs	31,499 shs
LNTH Lantheus	$81.49 +0.9%	$84.72	$73.11 ▼ $126.89	$5.64B	0.11	1.01 million shs	1.39 million shs
ROIV Roivant Sciences	$11.39 -1.8%	$11.11	$8.73 ▼ $13.06	$7.74B	1.17	5.62 million shs	11.13 million shs
RVMD Revolution Medicines	$36.91 -1.5%	$39.61	$29.17 ▼ $89.98	$6.88B	1.1	1.65 million shs	26.35 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-2.38%	-9.86%	-10.84%	+29.25%
LNTH Lantheus	0.00%	+2.90%	+7.92%	-16.51%	+1.49%
ROIV Roivant Sciences	0.00%	-0.52%	+3.73%	+12.88%	+7.76%
RVMD Revolution Medicines	0.00%	-6.93%	-7.68%	+4.38%	-4.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.6021 of 5 stars	3.5	2.0	0.0	3.8	0.8	0.6
LNTH Lantheus	4.3621 of 5 stars	3.5	1.0	4.2	1.9	2.5	1.9
ROIV Roivant Sciences	2.0429 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.0
RVMD Revolution Medicines	4.5174 of 5 stars	4.5	2.0	4.7	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	63.73% Upside
LNTH Lantheus	3.00	Buy	$130.50	60.14% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	53.64% Upside
RVMD Revolution Medicines	3.00	Buy	$67.58	83.10% Upside

Current Analyst Ratings Breakdown

Latest BLTE, ROIV, LNTH, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/24/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00 ➝ $73.00
6/24/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.72 per share	N/A
LNTH Lantheus	$1.53B	3.68	$7.09 per share	11.49	$15.65 per share	5.21
ROIV Roivant Sciences	$29.05M	266.54	N/A	N/A	$7.45 per share	1.53
RVMD Revolution Medicines	$11.58M	593.72	N/A	N/A	$13.47 per share	2.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$36.14M	-$1.36	N/A	N/A	N/A	N/A	-32.07%	-30.91%	8/8/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	23.15	12.91	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.00	N/A	N/A	N/A	N/A	-37.06%	-32.84%	8/6/2025 (Estimated)

Latest BLTE, ROIV, LNTH, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	24.31	24.31
LNTH Lantheus	0.49	5.74	5.46
ROIV Roivant Sciences	N/A	33.47	33.47
RVMD Revolution Medicines	N/A	13.46	13.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%
ROIV Roivant Sciences	64.76%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
LNTH Lantheus	2.00%
ROIV Roivant Sciences	7.90%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable
RVMD Revolution Medicines	250	186.27 million	170.99 million	Optionable

BLTE, ROIV, LNTH, and RVMD Headlines

Recent News About These Companies

Lunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 29 at 7:38 AM | marketbeat.com

Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Target Price at $67.58

June 29 at 2:17 AM | americanbankingnews.com

Q3 EPS Estimate for Revolution Medicines Raised by Analyst

June 27 at 6:19 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Guggenheim

June 26, 2025 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by Analysts

June 26, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Needham & Company LLC

June 26, 2025 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Given Outperform Rating at Wedbush

June 26, 2025 | americanbankingnews.com

Revolution Medicines' (RVMD) Buy Rating Reiterated at Guggenheim

June 25, 2025 | marketbeat.com

Wedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

Revolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | Nasdaq

June 24, 2025 | nasdaq.com

Needham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What Happened

June 24, 2025 | marketbeat.com

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

June 24, 2025 | reuters.com

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

June 24, 2025 | globenewswire.com

Revolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS ...

June 23, 2025 | finanznachrichten.de

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

June 23, 2025 | globenewswire.com

SG Americas Securities LLC Acquires 15,164 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

June 22, 2025 | marketbeat.com

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

June 19, 2025 | seekingalpha.com

GAMMA Investing LLC Purchases 20,696 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

June 18, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 13, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE, ROIV, LNTH, and RVMD Company Descriptions

Belite Bio NASDAQ:BLTE

$59.04 -0.86 (-1.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$60.75 +1.71 (+2.90%)

As of 04:05 AM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$81.49 +0.75 (+0.93%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$79.50 -1.99 (-2.44%)

As of 06:00 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.39 -0.21 (-1.81%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.80 +0.41 (+3.60%)

As of 04:00 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines NASDAQ:RVMD

$36.91 -0.57 (-1.52%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$89.98 +53.07 (+143.78%)

As of 04:00 AM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time